[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-degeneration":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,71,100,144,179,205,236,271,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100165906","cell-collection-to-study-eye-diseases-100165906",false,"NCT01432847","Cell Collection to Study Eye Diseases","Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls","* INCLUSION CRITERIA:\n\nTo be eligible, participants must meet the following inclusion criteria.\n\n1. Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or have a legally authorized representative if they are adults without consent capacity.\n2. Participant meets one of the following criteria:\n\n   1. Participant has been diagnosed with an ocular condition of interest including but not limited to: degenerative retinal diseases, optic atrophy, microphthalmia\u002Fanophthalmia, ciliopathy, and other ocular developmental or degenerative conditions.\n   2. Participant is free of eye diseases and could serve as an unaffected control. Participant's age, sex, and ethnicity must match an existing participant with one of the eye diseases under study. Control participants matched to AMD participants must not have drusen greater than 63 microns in size.\n3. Adult participant is able to provide a punch skin biopsy and 30 mL of peripheral venous blood OR child participant is able to provide a punch skin biopsy and the lesser of 5 mL\u002Fkg or 30 mL of peripheral venous blood. Healthy, unaffected children will only have one skin punch biopsy done 3mm or less in size. In affected participants, an additional punch may be gathered if the initial sample does not contain adequate cells. This will be taken from children ages seven years and older. Sampling of ten occipital hairs and\u002For saliva may be pursued at the investigator's discretion. Participants not able to provide a skin biopsy or blood sample may opt to provide 100-200 ml of fresh urine. As a rule, samples will be collected on non-sedated\u002Fanesthetized participants. Sedation\u002Fanesthesia will NOT be used solely for the purpose of sample collection. In rare instances where a minor requires sedation for another medically indicated procedure, samples may be collected at the time of sedation\u002Fanesthesia. Because young children may not be able to cooperate with sample collection, those unable to provide a skin biopsy, urine sample or a blood sample may be excluded from the study, based on the judgment of the examining investigator.\n4. Participant meets one of the following criteria:\n\n   1. Participant affected with an ocular condition is one year of age or older.\n   2. Participant affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n   3. Unaffected participant is seven years of age or older and willing and able to provide assent.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present.\n\n1. Participant is unable to comply with study procedures.\n2. Participant has a systemic disease that, in the opinion of the investigator, compromises the ability to provide adequate samples. Examples of co-existing diseases that would exclude a participant include a bleeding diathesis or a genetic susceptibility to infections, particularly cutaneous infections.\n\nADDITIONAL CRITERIA FOR CLNICAL-GRADE CELL LINE GENERATION:\n\nThe additional eligibility criteria must be met for participants donating samples for the generation of clinical-grade cell lines.\n\nInclusion Criteria\n\n1. Participant must be greater than 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment.\n2. Participant is able to provide a punch skin biopsy and 200 ml of peripheral venous blood.\n3. Participant is willing and eligible to co-enroll in NEI protocol 15-EI-0128.\n\nExclusion Criteria\n\n1. Participant has medical history that includes any of the following:\n\n   1. Thrombocytopenia or other blood dyscrasias\n   2. Bleeding diathesis\n   3. Antibiotic use within the prior 48 hours\n   4. Active cancer or history of cancer within the past five years\n   5. History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood\n\n      Banking and Transfusion Services, American Association of Blood Banks.\n   6. Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov\u002Ftravel)\n   7. At risk for the possible transmission of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, \"Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) by Blood and Blood Products\"\n2. Participant is currently febrile (temperature \\> 38 degrees C)\n3. Participant has Hemoglobin level:\n\n   * African American women \\\u003C11.5 grams\u002FdL\n   * Other women \\\u003C 12.0 grams\u002FdL\n   * Men \\\u003C12.5 grams\u002FdL\n4. Participant has low hematocrit (HCT):\n\n   * African American women \\\u003C 34%\n   * Other women \\\u003C36%\n   * Men \\\u003C38%\n5. Participant has Platelets \\\u003C150 x 103\u002FmicroL\n6. Participant has Absolute neutrophil count \\\u003C1.0 x 103\u002FmicroL.\n7. Participant has positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, American Association of Blood Banks. The currently required tests include anti-HIV1\u002F2, anti-HCV, anti-HBc, Anti-HTLV I\u002FII, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV, HBV, and HIV-1).",true,"ALL","1 Day","120 Years",{"count":21,"type":22},930,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect cells from people with Best disease, L-ORD, and AMD, and compare their cells with those of healthy volunteers.\n\nObjectives:\n\n\\- To collect hair, skin, saliva, urine, and\u002For blood samples to study three eye diseases that affect the retina: Best disease, L-ORD, and AMD.\n\nEligibility:\n\n* Individuals affected with ocular condition is one year of age or older.\n* Individuals affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n* Unaffected individuals are seven years of age or older.\n\nDesign:\n\n* The study requires one visit to the National Eye Institute.\n* Participants will be screened with a medical and eye disease history. They may also have an eye exam.\n* Participants will provide a hair sample, saliva sample, urine sample, blood sample, and\u002For a skin biopsy. The hair will be collected from the back of the head, and the skin will be collected from the inside of the upper arm.",[26,27,28,29],"Retinal Disease","AMD","Retinal Degeneration","Retinitis Pigmentosa",[31,32,33,34,28,35,27],"Best Disease","Late-Onset Retinal Degeneration (L-ORD)","Age-Related Macular Degeneration (AMD)","Natural History","Age-Related Macular Degeneration","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2011-09-07",{"name":44,"class":45},"National Eye Institute (NEI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100256498","rod-and-cone-mediated-function-in-retinal-disease-100256498","NCT02617966","Rod and Cone Mediated Function in Retinal Disease","* INCLUSION CRITERIA:\n* Participant must be five years of age or older.\n* Participant (or legal guardian) must understand and sign the protocol s informed consent document.\n* Participant must be able to cooperate with the testing required for this study.\n\nFor Participants with retinal disease only:\n\n* Participant must have retinal disease, defined as evidence of loss of retinal dysfunction and\u002For degeneration as established by standard clinical methods including perimetry, ERG and imaging.\n* Participant must have a measurable visual acuity.\n\nFor Healthy Volunteers only:\n\n-Participant must have visual acuity of 20\u002F20 or better, with or without correction (e.g., glasses or contact lens) in at least one eye.\n\nEXCLUSION CRITERIA:\n\n-Participant with changes in pre-retinal media sufficient to obscure a view of the retina.","5 Years","100 Years",{"count":56,"type":22},500,"Background:\n\nRetinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.\n\nObjectives:\n\nTo find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track its changes.\n\nEligibility:\n\nPeople ages 5 and older with:\n\nRetinal disease OR\n\n20\u002F20 vision or better with or without correction in at least one eye\n\nDesign:\n\nParticipants will be screened with medical and eye history and eye exam. Those with retinal disease will also have:\n\nEye imaging: Drops dilate the eye and pictures are taken of it.\n\nVisual field testing: Participants look into a bowl and press a button when they see light.\n\nElectroretinogram (ERG): An electrode is taped to the forehead. Participants sit in the\n\ndark with their eyes patched for 30 minutes. Then they get numbing drops and contact\n\nlenses. Participants watch lights while retina signals are recorded.\n\nVisit 1 will be 3-8 hours. Participants will have up to 6 more visits over 6-12 months. Visits include:\n\nEye exam and imaging\n\nTime course of dark adaptation: Participants view a background light for 5 minutes then\n\npush a button when they see colored light.\n\nDark adapted sensitivity: Participants sit in the dark for 45 minutes. They push a button when\n\nthey see colored light.\n\nFor participants with retinal disease, ERG and visual field testing",[28,29,59],"Stargardt's Disease",[61,28,29,59,62],"Retina","Dark Adaptation","2026-05-28",{"date":65,"type":40},"2026-05-29",{"date":67,"type":40},"2016-03-24",{"date":69,"type":22},"2029-12-30",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567","NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","21 Years",{"count":79,"type":22},100,"The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[28,35,29,82,83,84,85,86,87,88],"Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Dystrophy","Cone Rod Dystrophy","Rod Cone Dystrophy","Rod Dystrophy","2026-05-06",{"date":91,"type":40},"2026-05-08",{"date":93,"type":40},"2021-08-27",{"date":95,"type":22},"2028-09-30",{"name":97,"class":98},"Food and Drug Administration (FDA)","FED",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":112,"briefSummary":115,"conditions":116,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":143},"100576757","phase-1-a-study-to-investigate-the-safety-of-opct-001-in-adults-who-have-primary-photoreceptor-disease-clarico-100576757","NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)","A Phase 1\u002F2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease","CLARICO","Key Inclusion Criteria:\n\n* Confirmed genetic diagnosis of primary photoreceptor (PR) disease\n* Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.3. BCVA at Screening for Phase 2: ETDRS letter score between 20 to 60, inclusive.\n* Retinal structure examination in the study eye demonstrating regions suitable for cell administration.\n\nKey Exclusion Criteria:\n\n* Clinically relevant, active ocular inflammation or infection\n* Glaucoma or other significant optic neuropathy\n* Diabetic macular edema or diabetic retinopathy\n* Clinically significant cystoid macular edema\n* In phakic participants: Spherical equivalent refractive error of greater than 8.00 diopters myopia\n* Ocular surgery ≤3 months before Screening\n* Monocular vision (ie, no light perception in the fellow eye)\n* Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.\n* Any current and active infection (bacterial\u002Fviral\u002Ffungal) that could put the participant at risk from immunosuppression\n* History of any cell therapy, gene therapy, or retinal implant at any time\n* Previously received a bone marrow or solid organ transplant","18 Years",{"count":110,"type":22},54,"INTERVENTIONAL",[113,114],"PHASE1","PHASE2","Study OpCT-001-101 is a Phase 1\u002F2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.",[117,118,119,120,121,122,28,123,124],"Primary Photoreceptor Disease","Retinitis Pigmentosa (RP)","Usher Syndrome","Inherited Retinal Disease (IRD)","Rod-Cone Dystrophy","Rod-Cone Disease","Cone-Rod Disease (C-RD)","Cone-Rod Dystrophy",[106,126,127,128,119,29,129,130,131,132],"Photoreceptor cells","Cell Therapy","Cellular Therapy","Inherited retinal disease (IRD)","Primary Photoreceptor disease (PPD)","Rod-Con Disease (R-CD)","Cone-Rose disease (C-RD)","2026-04-07",{"date":135,"type":40},"2026-04-13",{"date":137,"type":40},"2025-03-10",{"date":139,"type":22},"2030-10",{"name":141,"class":142},"BlueRock Therapeutics","INDUSTRY",4,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":111,"phases":156,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100613674","early-phase-1-first-in-human-dose-escalation-trial-of-axv-101-in-bbs1-related-retinal-degeneration-100613674","NCT07269665","First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration","A First-In-Human, Open Label, Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Dose of AXV-101 in Patients With Bardet-Biedl Syndrome 1 (BBS1) Bi-Allelic Mutations and Retinal Degeneration","AXIS","To be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Male or female participants aged 4 to 17 years (inclusive).\n2. Able to provide written informed consent:\n\n   2.1. Parent(s)\u002Fguardian(s) prior to the initiation of any study-specific procedures for participants who are under the age of 18 2.2. Participants aged 6-17 years of age may (according to the judgement of the investigator) provide their written assent; consent will also be required from the legal guardian of the participant.\n\n   2.3. Participants aged below 6 years of age will not be required to sign an assent form; however, their views should be considered; consent will be required from the legal guardian of the participant.\n3. Participant with a confirmed diagnosis of bi-allelic BBS1 mutations. Molecular diagnosis\u002Fgenetic testing will have been undertaken by an accredited laboratory using an assay that has the relevant mark of conformity and is used as per its intended use. UK diagnostic genetic laboratories must conform to the Association for Clinical Genomic Science (ACGS) and adopt the ACMG guidelines for the determination of pathogenicity. US diagnostic genetic laboratories must be CLIA-approved.\n4. Participants with presentation of retinal degeneration (evidence of early Rod-Cone Dystrophy, Cone-Rod Dystrophy or Night vision loss \\[nyctalopia\\])\n5. Participants with sufficient viable retinal cells as determined by OCT. Participants must have either:\n\n   5.1. A measurable area of intact ellipsoid within the posterior pole - minimum 1500 microns horizontal width 5.2. ≥3-disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or 5.3. Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.\n6. Post-pubertal male participants and female participants of childbearing potential must be willing to comply with the contraceptive requirements\n\nAn individual who meets any of the following criteria will be excluded from participation in this trial:\n\n1. A fully blind participant.\n2. Participant or participant's legal guardian is unable or unwilling to meet the requirements of the study, or unable to provide written informed consent\u002Fassent\n3. Participant has been administered any investigational medicinal product (IMP) during the last 6 months prior to individual enrolment of the participant and\u002For within five half-lives of the previous IMP, whichever is longer\n4. Other than as required per protocol, the participant has received immune-modulating agents within 90 days before dosing (use of inhaled corticosteroids to manage chronic respiratory conditions is allowed)\n5. Glucocorticoid intolerance\n6. Use of other concomitant medications to manage chronic conditions must have been stable for at least 30 days before dosing\n7. Presence of severe diabetes or uncontrolled blood glucose\n8. Presence of active infection or recent severe infection (elevated WBC)\n9. Participant with any prior intraocular surgery in either eye within 6 months\n10. Participant with any known sensitivity to AXV-101, its excipients and the medications planned for use in the peri-operative period\n11. Participant with significant renal, liver or haematological disease as defined by:\n12. Laboratory evidence of liver disease (aspartate aminotransferase greater than two times the upper limit of normal \\[ULN\\] of the testing laboratory).\n13. Laboratory evidence of renal disease (eGFR\\\u003C30).\n14. Laboratory evidence of haematological disease (absolute neutrophil count \\\u003C 1,500\u002Fmm3; haemoglobin \\\u003C 0.9 times the lower limit of normal \\[LLN\\] of the testing laboratory, by sex; or platelet count \\\u003C 140,000\u002Fmm3).\n15. Any pre-existing eye conditions or complicating systemic diseases that would preclude the planned surgery or interfere with the interpretation of the study or the safety of the participant. Active uveitis or intraocular inflammation (infectious or non-infectious). Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example: radiation treatment of the orbit; leukaemia with central nervous system (CNS)\u002Foptic nerve involvement). Participants with diabetes or sickle cell disease will be excluded if they have had any manifestation of advanced retinopathy (e.g., macular oedema or proliferative changes). Also excluded would be participants with immunodeficiency (acquired or congenital), as there could be susceptibility to opportunistic infection (such as cytomegalovirus retinitis).\n16. Participants with evidence of chronic or active viral disease, including:\n17. Participant has human immunodeficiency virus HIV-1 or HIV-2, including serological or viral load evidence of HIV 1 or HIV-2.\n18. Participant has an active viral infection (systemic bacterial or fungal infection) based on clinical observation.\n\n    18.1. Active hepatitis B (HBV) or C (HCV), and HBsAg, HBcAb, HBV-DNA positivity or HCV-Ribonucleic acid (RNA) viral load positivity, respectively. A negative viral load assay in two samples, collected at least 6 months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible.\n19. Any other circumstance that would not allow the potential participant to complete follow-up examinations during the course of the study or, in the opinion of the Investigator, makes the potential participant unsuitable for the study.\n20. Pregnant and\u002For breastfeeding participant.","4 Years","17 Years",{"count":155,"type":22},12,[157],"EARLY_PHASE1","The goal of this first in human study is to evaluate the preliminary safety and tolerability of AXV-101 in participants with BBS1. The main questions it aims to answer are:\n\n* Is AXV-101 safe and tolerable to use in participants with BBS1?\n* To determine the therapeutic dose of AXV-101 in participants with BBS1\n* To investigate the concentration of AXV-101 in blood, urine and tears (both eyes)\n\nParticipants will undergo comprehensive ophthalmic assessments to evaluate functional and structural changes from baseline to one year in the treated eye compared with the untreated eye. Additional evaluations will include blood, urine, and tear testing for safety and pharmacokinetics, and quality of life questionnaires completed by both participants and caregivers. Safety will also be assessed by monitoring the frequency and severity of adverse events, including serious adverse events, through medical history, physical examinations, and laboratory testing.",[160,28],"Bardet-Biedl Syndrome 1",[162,163,164,165,166,167,168],"bi-allelic mutations","retinal degeneration","first-in-human","Bardet-Biedl syndrome 1","BBS1","gene therapy","children","NOT_YET_RECRUITING","2026-03-30",{"date":172,"type":40},"2026-03-31",{"date":174,"type":22},"2026-05",{"date":176,"type":22},"2032-02",{"name":178,"class":142},"Axovia Therapeutics",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":111,"phases":190,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":143},"100625675","multicenter-study-of-transcranial-magnetic-stimulation-on-vision-restoration-100625675","NCT07425717","Multicenter Study of Transcranial Magnetic Stimulation on Vision Restoration","Effectiveness of TMS for Visual Restoration: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* between 45 and 70 years old\n* bilateral severe MMD (META-PM grades ≥ 3)\n* no prior TMS history or contraindications to TMS\n\nExclusion Criteria:\n\n* other significant ocular diseases, such as refractive media opacity, glaucoma, uveitis, ocular trauma, untreated retinal detachment, or lens dislocation\n* received anti-vascular endothelial growth factor treatment or other ocular surgeries within 3 months\n* history of epilepsy or family history of epilepsy, intracranial metal implants, or severe cerebrovascular diseases\n* mental illness, cognitive impairment (MMSE score \\\u003C 24), unable to communicate effectively\n* severe heart disease, liver or kidney dysfunction, or coagulation disorders\n* pregnant or lactating women\n* currently participating in other clinical trials.","45 Years","70 Years",{"count":189,"type":22},136,[191],"NA","The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:\n\n1. Does TMS treatment improve the visual function of participants?\n2. What medical problems do participants have when receiving TMS treatment? Researchers will compare TMS treatment to a sham stimulation (identical procedures using a sham coil without effective magnetic field output) to see if TMS treatment works to restore their vision.\n\nParticipants will:\n\nUndergoTMS treatment to a sham stimulation for consecutive 5 days Visit the clinic at 5 days, 4 weeks, 3 months, 6 months, 12 months after start of the treatment for checkups and tests",[28,194],"Vision Impairment and Blindness","2026-02-20",{"date":197,"type":40},"2026-02-23",{"date":199,"type":22},"2026-06-01",{"date":201,"type":22},"2029-05-31",{"name":203,"class":204},"Shanghai High Myopia Study Group","OTHER",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":212,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":111,"phases":215,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":46},"100606371","phase-2-sglt2-inhibitors-in-geographic-atrophy-100606371","NCT07174687","SGLT2 Inhibitors in Geographic Atrophy","Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n3. Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year\n4. ≥50 years old\n5. Evidence of dry advanced AMD with the presence of non-foveal Geographic Atrophy (GA)\n\n   1. The geographic atrophy must not involve the center point of the fovea.\n   2. Total area of geographic atrophy must be between 2.5 mm2 and 17.5 mm2 (1 - 4 disc areas, respectively).\n   3. If the geographic atrophy consists of multiple lesions, at least one lesion must have an area of ≥1.25 mm² (equivalent to 0.5 disc areas).\n6. BCVA between 20\u002F25 and 20\u002F320\n7. Must be treatment-naïve for AMD, except for oral supplements\n\nExclusion Criteria:\n\n1. Prior investigational drug use within 60 days\n2. Use of other SGLT2 inhibitors\n3. History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP \\\u003C 90mmHg) at baseline\n4. Type I and Type II Diabetes Mellitus\n5. End stage renal disease or estimated glomerular filtration rate less than 25 mL\u002Fmin\u002F1.73 m2 per MDRD calculation\n6. History of heart failure\n7. History of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA\n8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures\n9. Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins or mineral\n10. Any intraocular surgery or thermal laser within 3 months of date of randomization\n11. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks\n12. Any prior thermal laser in the macular region, regardless of indication (self-report)\n13. Any evidence of choroidal neovascularization in study eye\n14. Enrollment in another interventional trial during the trial period","50 Years",{"count":214,"type":22},70,[114],"AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.",[28,218,219,220,221],"Retinal Diseases","Eye Diseases","Geographic Atrophy","Pathological Conditions, Anatomical",[223,224,27,225,226],"Geographic Atrophy (GA)","Age-related Macular Degeneration","SGLT2","Dapagliflozin","2025-12-16",{"date":229,"type":40},"2025-12-18",{"date":231,"type":40},"2025-12-02",{"date":233,"type":22},"2028-06",{"name":235,"class":204},"Washington University School of Medicine",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":16,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":111,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":46},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",{"count":245,"type":22},1200,[191],"Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[29,249,250,251,252,28,253,254,255,256,257,258,259,260,261],"Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Detachment","Glaucoma","Vascular Inflammation","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":264,"type":40},"2025-11-18",{"date":266,"type":40},"2019-07-03",{"date":268,"type":22},"2027-07",{"name":270,"class":204},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":111,"phases":279,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":46},"100539559","phase-3-a-efficacy-and-safety-study-of-ranibizumab-10mgml-injection-incepta-in-patients-with-diabetic-macular-edema-100539559","NCT06305416","A Efficacy and Safety Study of Ranibizumab 10mg\u002Fml Injection (Incepta) in Patients With Diabetic Macular Edema","Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg\u002Fml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection","Inclusion Criteria:\n\n1. Ages Eligible for Study: ≥ 18 Years\n2. Ability to provide written informed consent and comply with study assessments for the full duration of the study\n3. Diagnosis of diabetes mellitus (type 1 or 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Laboratory reports that prove DM of patient or current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemic agent for the treatment of diabetes.\n4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula (can be associated with diabetic retinopathy)\n5. Central diabetic macular edema present on clinical examination and OCT testing with central 1mm sub field thickness greater than 300 microns as measured on -OCT\n6. Visual acuity score greater than or equal to 19 letters (20\u002F400) and less than or equal to 73 letters (20\u002F40) by the ETDRS\u002F Snellen chart visual acuity protocol\n7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography\n8. Willingness and ability to undertake all scheduled visits and assessments\n\nExclusion Criteria:\n\n1. Prior treatment with any Intravitreal drug, Bevacizumab, verteporfin or photodynamic therapy (except for extra foveal laser photocoagulation) in the study eye within past 3 months before study entry\n2. Laser photocoagulation in the study eye within 1 month before study entry\n3. Participation in another ocular investigation or trial simultaneously\n4. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.\n5. Blood pressure \\> 160\u002F100 mmHg (systolic above 160 or diastolic above 100) and Random Blood Sugar (RBS) ≥ 12 mmol\u002FL and\u002F or HbA1c ≥ 7.5%\n6. Evidence of vitreoretinal interface abnormality and optic nerve disease after ocular exam or OCT that may be contributing to the macular edema\n7. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. cataract that might decrease the vision by 3 or more lines, uncontrolled glaucoma, uveitis, previous corneal transplant etc.). The decision regarding exclusion is to be based on the opinion of the investigator.\n8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of sub retinal fibrosis or geographic atrophy).\n9. Presence of suspected ocular or periocular infections, another ocular condition that may affect the visual acuity or macular edema during the course of the study (uveitis, Irvine-Gas)\n10. Vitreous hemorrhage preventing visualization of retina\n11. History of vitreous surgery, cataract surgery, YAG capsulotomy in the study eye within last 3 months of enrolment\n12. Visual acuity \\\u003C20\u002F400 in the fellow eye\n13. Known hypersensitivity to Ranibizumab or any of the components of study medication\n14. History of cerebral vascular accident or myocardial infarction within past 3 months.\n15. Employees of Investigational sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.\n16. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine\u002F hydroxychloroquine, tamoxifen, phenothiazine, vigabatrin and ethambutol, and such medications will not be allowed during the study period.",{"count":214,"type":22},[280],"PHASE3","Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema.\n\nDiabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus.\n\nThe use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.",[283,284,251,285,26,28],"Diabetic Macular Edema","Diabetic Retinopathy","Macular Degeneration",[287,288,257,61,289],"Ranibizumab","Efficacy","Edema","2025-06-03",{"date":292,"type":40},"2025-06-06",{"date":294,"type":40},"2024-03-30",{"date":296,"type":22},"2025-12",{"name":298,"class":142},"Incepta Pharmaceuticals Ltd",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":187,"enrollmentInfo":306,"targetDuration":4,"studyType":111,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":46},"100475730","phase-1-minocycline-for-chronic-autoimmune-uveitis-100475730","NCT05474729","Minocycline for Chronic Autoimmune Uveitis","The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis","Inclusion Criteria:\n\n* Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure)\n* Participant aged from 18-60 years old.\n* Participant that signed the informed consent document and is able to complete the following visits.\n\nExclusion Criteria:\n\n* Participant is allergy to minocycline or tetracyclines.\n* Participant has no contraindications of minocycline or tetracyclines.\n* Participant has an abnormal function of liver, heart, kidney and thyroid.\n* Participant is using glucocorticoids, immunosuppressants or biologics.\n* Female that is pregnant, breast-feeding or planning to become pregnant.\n* Participant that is currently using other medications for other diseases.",{"count":5,"type":22},[113,114],"Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.",[310,311,28],"Minocycline","Uveitis","2023-04-16",{"date":314,"type":40},"2023-04-18",{"date":316,"type":40},"2021-12-01",{"date":318,"type":22},"2026-12-31",{"name":320,"class":204},"Sun Yat-sen University"]